The cost-effectiveness body rejected Cinqaero (reslizumab) in the autumn, citing uncertainties in clinical data provided by Teva. But Teva's discount and further cost-effectiveness analysis has ...

It is the third biological treatment for severe eosinophilic asthma approved for NHS use by NICE, following GSK’s Nucala (mepolizumab) in December 2016 and Teva’s Cinqaero (reslizumab ...